Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAXOMAT in Noonan Syndrome
NCT00452725Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 1997
- Primary completion
- Jul 2010
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin in Noonan syndrome, sponsored by Sanofi. Primary endpoints: Evaluation of height: gain in height and Evaluation of height: rate of growth. Started Oct 1997; status: completed.
02
Drugs
somatropin
03
Conditions
Noonan syndrome
Beyond the preview
Go deeper on NCT00452725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452725.